Devlin A M, Gordon J F, Davidson A O, Clark J S, Hamilton C A, Morton J J, Campbell A M, Reid J L, Dominiczak A F
Department of Medicine and Therapeutics, University of Glasgow, UK.
J Hypertens. 1995 Feb;13(2):211-8.
To quantify vascular smooth muscle polyploidy and growth kinetics in aortic cells from stroke-prone spontaneously hypertensive rats (SHRSP) and from normotensive Wistar-Kyoto (WKY) rats, and to examine the effects of treatment with the angiotensin converting enzyme (ACE) inhibitor perindopril on these parameters.
The following experimental groups were used: young (age < 20 weeks) and old (age > 20 weeks) untreated WKY rats and untreated SHRSP; SHRSP treated with perindopril, and age- and sex-matched control SHRSP; and SHRSP treated with hydralazine and hydrochlorothiazide and age- and sex-matched control SHRSP. The effects of treatment of the SHRSP with perindopril for 30 days on vascular smooth muscle polyploidy and growth kinetics were measured and compared with the effects of equivalent antihypertensive doses of hydralazine and hydrochlorothiazide.
Vascular smooth muscle polyploidy was measured using flow-cytometry DNA analysis of freshly harvested cells. Growth curves were performed on cultured aortic cells. Plasma renin activity was measured by an antibody-trapping method, plasma angiotensin II (Ang II) by radioimmunoassay and plasma ACE activity by a colorimetric method. Cardiac hypertrophy was evaluated by measuring the heart weight:body weight and left ventricle + septum weight:body weight ratios.
The SHRSP had markedly and significantly elevated G2 + M phase of the cell cycle. Treatment with perindopril resulted in a significant reduction in polyploidy in the SHRSP, whereas treatment with hydralazine and hydrochlorothiazide had no effect on the percentage of cells in the G2 + M phase of the cell cycle. The regression of polyploidy after treatment with perindopril was associated with a significant reduction in the concentration of Ang II and ACE activity, and with a significant regression of cardiac hypertrophy. Increased mitogenesis of cultured vascular smooth muscle cells from the SHRSP was not altered by treatment with perindopril.
ACE inhibition reduces vascular smooth muscle polyploidy in large conduit arteries. This type of vascular protection is mediated by the reduced Ang II and possibly by increased kinins level, rather than by the hypotensive effect alone.
量化易卒中型自发性高血压大鼠(SHRSP)和正常血压的Wistar-Kyoto(WKY)大鼠主动脉细胞中的血管平滑肌多倍体和生长动力学,并研究血管紧张素转换酶(ACE)抑制剂培哚普利治疗对这些参数的影响。
使用以下实验组:年轻(年龄<20周)和年老(年龄>20周)未治疗的WKY大鼠和未治疗的SHRSP;用培哚普利治疗的SHRSP,以及年龄和性别匹配的对照SHRSP;用肼屈嗪和氢氯噻嗪治疗的SHRSP,以及年龄和性别匹配的对照SHRSP。测量培哚普利治疗SHRSP 30天对血管平滑肌多倍体和生长动力学的影响,并与等效降压剂量的肼屈嗪和氢氯噻嗪的影响进行比较。
使用新鲜收获细胞的流式细胞术DNA分析测量血管平滑肌多倍体。对培养的主动脉细胞进行生长曲线测定。通过抗体捕获法测量血浆肾素活性,通过放射免疫测定法测量血浆血管紧张素II(Ang II),通过比色法测量血浆ACE活性。通过测量心脏重量:体重和左心室+室间隔重量:体重比来评估心脏肥大。
SHRSP的细胞周期G2 + M期明显且显著升高。培哚普利治疗导致SHRSP中的多倍体显著减少,而肼屈嗪和氢氯噻嗪治疗对细胞周期G2 + M期的细胞百分比没有影响。培哚普利治疗后多倍体的消退与Ang II浓度和ACE活性的显著降低以及心脏肥大的显著消退相关。SHRSP培养的血管平滑肌细胞增加的有丝分裂活性不受培哚普利治疗的影响。
ACE抑制可降低大血管动脉中的血管平滑肌多倍体。这种类型的血管保护是由Ang II减少介导的,可能是通过激肽水平升高,而不是仅通过降压作用。